SCM
ALNY icon

Sigma Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sigma Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-140,000
Closed -$4.34M – 282
2013
Q2 		$4.34M Buy
+140,000
New +$3.73M 0.2% 117

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Sigma Capital Management's ALNY Position: Q3 2013 in Review

Sigma Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2013, closing a stake of 140,000 shares — an estimated $4.34M sold.

Sigma Capital Management first reported a position in ALNY in Q2 2013 and held it in 1 quarter. The position peaked at $4.34M in Q2 2013. 164 funds tracked by Wall St. Rank hold ALNY as of Q3 2013.

  • Sigma Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Sigma Capital Management sold 140,000 Alnylam Pharmaceuticals shares in Q3 2013, an estimated $4.34M.
  • Sigma Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Sigma Capital Management's Alnylam Pharmaceuticals position peaked at $4.34M in Q2 2013.
  • 164 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2013.

Based on Sigma Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.